A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms CGAN study
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 12 Sep 2023 Results of a post-hoc analysis assessing consistency of galcanezumab efficacy through the monthly dosing interval published in the Neurology and Therapy
- 20 Oct 2022 Results of secondary analysis assessing the effect of galcanezumab on migraine headache severity, frequency of migraine-associated symptoms, and frequency of migraine headaches during menstrual periods in Japanese patients with episodic migraine, published in the Neurology and Therapy.
- 20 Jun 2020 Results assessing quality of life questionnaire presented at the 62nd Annual Scientific Meeting of the American Headache Society